What is BlueSphere Bio?
BlueSphere Bio is a biotechnology firm dedicated to pioneering TCR-based therapies for a range of challenging medical conditions. The company's strategic focus encompasses hematologic malignancies, solid tumors, and rare diseases, with a clear vision to provide curative options for cancer patients. Key clinical programs include the development of therapies such as TCX-101 and TCX-102, representing a commitment to advancing cancer treatment through cutting-edge technology and rigorous research.
How much funding has BlueSphere Bio raised?
BlueSphere Bio has raised a total of $45M across 1 funding round:
Series B
$45M
Series B (2021): $45M, investors not publicly disclosed
What's next for BlueSphere Bio?
The recent major strategic investment positions BlueSphere Bio for accelerated growth and the advancement of its therapeutic pipeline. This capital infusion is expected to fuel further research and development, potentially enabling the company to move its promising TCR-based therapies, including TCX-101 and TCX-102, closer to clinical application. The company's focus on hematologic malignancies, solid tumors, and rare diseases suggests a strategic expansion into critical areas of unmet medical need, aiming to solidify its position as an innovator in cancer therapeutics.
See full BlueSphere Bio company page
